Twist Bioscience Corporation (NASDAQ: TWST) is a Healthcare company (Biotechnology) with a market capitalization of $7.4B. The Maz Rating grades it against the other companies in its sector.
Twist Bioscience Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $112.00, Twist Bioscience Corporation trades at 15.9x sales and 7.8x book value. Over the last twelve months it generated about $465M of revenue and a net loss of $139M. It runs a gross margin of 52.4%, an operating margin of -30.4% and a net margin of -28.3%. It shows return on equity of -23.2%, return on invested capital of -13.8% and a free cash flow yield of -1.2%. On the balance sheet: a debt-to-equity ratio of 0.11 and a current ratio of 5.86. Over the past 52 weeks the share price ranged from $24.41 to $219.71, with a beta of 2.22.
Twist Bioscience Corporation does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 11 Buy, 2 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Twist Bioscience Corporation (TWST) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 7.11% / 30% · Interest income / Revenue 2.70% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 6.37% / 33% · Receivables / Mkt Cap (36m) 0.77% / 49% · Interest income / Revenue 2.70% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 6.37% / 33.33% · Receivables / Mkt Cap (24m) 0.77% / 33.33% · Interest income / Revenue 2.70% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 3.43% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 36.0% / 33.33% · Receivables / Avg Assets (4Q) 8.05% / 33.33% · Interest income / Revenue 2.70% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 51.9% / 33.33% · (Cash+Recv) / Total Assets 58.1% / 33.33% · Interest income / Revenue 2.70% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Twist Bioscience Corporation (TWST) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Twist Bioscience Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.70% of each dividend: Twist Bioscience Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q4 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.